Oxlumo™ (lumasiran) – Expanded indication
October 6, 2022 - Alnylam Pharmaceuticals announced the FDA approval of Oxlumo (lumasiran), for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.
Download PDF
